Skip to content

A cohort study about the role of PD-1/PD-L1 in evaluating the prognosis of prostate cancer receiving therapy

A cohort study about the role of PD-1/PD-L1 in evaluating the prognosis of prostate cancer receiving therapy

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR-POC-17012719
Enrollment
Unknown
Registered
2017-09-18
Start date
2017-09-30
Completion date
Unknown
Last updated
2018-05-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prostate cancer

Interventions

PD-1 positive/PD-L1 positive :none
PD-1 positive/PD-L1 negative:none
PD-1 negative/PD-L1 positive:none
PD-1 negative/PD-L1 negative:none

Sponsors

Department of Urology Laboratory, Tongji Medical College, Huazhong University of Science and Technology
Lead Sponsor

Eligibility

Sex/Gender
Male

Inclusion criteria

Inclusion criteria: Patients who are diagnosised of prostate cancer by biopsy, needed to receive treatment.

Exclusion criteria

Exclusion criteria: (1) Patient who has serious heart,lung,liver or kidney disease; (2) Patient who refusing to accept treatment; (3) Patient who failed to regulate treatment with the orders requirements;

Design outcomes

Primary

MeasureTime frame
PD-1/PD-L1 immuno-histochemistry;

Countries

China

Contacts

Public ContactYe Zhangqun

Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology

zhangqun_ye@163.com+86 027-83663460

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026